医药行业周报:礼来首个小分子口服GLP-1药物3期临床研究成功 有望改变减重药物格局

平安证券股份有...
20 Apr

行业观点礼来首个小分子口服GLP-1药物3期临床研究成功,有望改变减重药物格局4月17日,全球制药巨头礼来公司公布了3期临床研究ACHIEVE-1的积极顶线结果,该研究评估了Orforglipron与安慰剂相比,在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。据礼来介绍,Orforglipron是首款无需饮食、饮水控制的口服小分子GLP-1受体激动剂。若获得上市批准,公司有信心...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10